Nordic Nanovector, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics in hematology and oncology. Its lead clinical-stage product candidate is Betalutin, an antibody-radionuclide-conjugate, which is in Phase I/II clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. The Company has a collaboration agreement with AREVA Med and Paul Scherrer Institute to develop antibody-drug conjugates for treating leukaemias; and LegoChem Biosciences and Heidelberg Pharma to develop Antibody Radionuclide conjugates.
Market capitalization (8-Jan-2021)
Closing stock price (8-Jan-2021)
When was Nordic Nanovector founded?
Nordic Nanovector was founded in 2009.
Who are Nordic Nanovector key executives?
Nordic Nanovector's key executives are Jean-Pierre Bizzari, Rainer Boehm and Marco Renoldi.
How many employees does Nordic Nanovector have?
Nordic Nanovector has 37 employees.
Who are Nordic Nanovector competitors?
Competitors of Nordic Nanovector include Y-mAbs Therapeutics, Molecular Partners and Abliva.
Where is Nordic Nanovector headquarters?
Nordic Nanovector headquarters is located at 168 Kjelsåsveien, Oslo.
Where are Nordic Nanovector offices?
Nordic Nanovector has offices in Oslo, Zug and Shrewsbury.
How many offices does Nordic Nanovector have?
Nordic Nanovector has 3 offices.
Receive alerts for 300+ data fields across thousands of companies